Table 4.

List of RNA-encapsulated lipid nano-particles (LNPs) with indication and clinical trial information.

Drug and Its Sponsor	Target	Clinical Trial	Indication	Ref.
DCR-MYC Dicerna Pharmaceuticals, Inc.	Oncogene MYC	Terminated, Phase I, II NCT02314052, NCT02110563	Solid tumors, hepatocellular Carcinoma	[26,99]
TKM-080301 Arbutus Biopharma Corporation (Warminster, PA, USA)	PLK1 (polo-like kinase-1)	Completed, Phase I, II NCT01262235, NCT02191878	Gastrointestinal neuroendocrine tumors, adrenocortical carcinoma tumors, advanced hepatocellular carcinoma	[26,94,95,96]
EphA2 siRNA M.D. Anderson Cancer Center National Cancer Institute (NCI)	EphA2	Recruiting, Phase 1 NCT01591356	Advanced Malignant Solid Neoplasm	[26,101,103]
ARB-001467 Arbutus Biopharma Corporation	HBsAg	Completed, Phase II NCT02631096	Hepatitis B, Chronic	[26]
PRO-040201 Arbutus Biopharma Corporation	ApoB	Terminated, Phase I (Potential for immune stimulation to interfere with further dose escalation.) NCT00927459	Hypercholesterolemia	[26]
ALN-PCS02 Alnylam Pharmaceuticals	PCSK9	Completed, Phase I NCT01437059	Elevated LDL-cholesterol	[26]
ND-L02-s0201 Bristol-Myers Sqyubb Pharmaceuticals	HSP47	Completed, Phase I NCT02227459	Hepatic fibrosis	[26]
ARC-520 Arrowhead Pharmaceuticals and ICON Clinical Research	HBsAg	Terminated, Phase 2 NCT02065336	Chronic Hepatitis B Virus	[23]
DCR HBVS Dicerna Pharmaceuticals, Inc.	HBsAg	Recruiting, Phase 1 NCT03772249	Hepatitis B, Chronic	[23,104]
ALN-VSP02 Lipid Nanoparticle	siRNA-KSP	Completed, Phase 1, NCT01158079	Cancer- Solid tumors	[105,106,107]
mRNA-2752 Lipid Nanoparticle Moderna Tx. Inc. (Cambridge, MA, USA) and AstraZeneca (Cambridge, UK)	OX40L T cell	Recruiting, Phase 1 NCT03739931	Cancer- various	[108,109]
mRNA-2416 Lipid Nanoparticle ModernaTX, Inc.	OX40L T cell	Recruiting, Phase 1–2, NCT03323398	Cancer- Solid Tumor,Lymphoma, Ovarian	[110]
Liposomal T4N5 Lotion National Cancer Institute (NCI)	a prokaryotic DNA repair enzyme	Completed Phase 2 NCT00089180	The Recurrence of Nonmelanoma Skin Cancer	[111]